3 researchers to receive prestigious awards from the American Society of Hematology

August 12, 2008

(WASHINGTON, August 12, 2008) - The American Society of Hematology (ASH), the world's largest professional society of blood specialists, will honor three scientists who have made significant contributions to the understanding of hematologic diseases.

At the 2008 ASH Annual Meeting, Clara D. Bloomfield, MD, of the The Ohio State University in Columbus, OH, will be presented with the Henry M. Stratton Medal, intended to honor an individual whose well-recognized contributions to hematology have taken place over a period of several years. Dr. Bloomfield will receive this award for her remarkable achievements in the area of hematologic malignancies, especially acute myelogenous leukemia, for more than three decades. Dr. Bloomfield has been a major contributor to the understanding of the biology of these diseases and the practical use of biologic information in diagnosis, classification, and determining prognosis and selection of curative therapeutic approaches.

Kenneth Anderson, MD, of the Dana-Farber Cancer Institute in Boston, MA, will be presented with the William Dameshek Prize, awarded to an individual who has made a recent outstanding contribution to the field. Dr. Anderson will be recognized for his contributions to the treatment of myeloma. He has advanced the field by establishing a new paradigm focused not only on the malignant cell, but also on the microenvironment for the identification of molecularly-targeted therapies. His rapid translations of his pre-clinical discoveries into phase I-III trials have substantially improved the clinical outcome for myeloma patients.

Robert Kyle, MD, of the Mayo Clinic in Rochester, MN, will be presented with the Wallace H. Coulter Award for Lifetime Achievement in Hematology, which was established in 2007 to honor individuals who have made a lifelong commitment to the specialty and whose contributions have had a major impact on education, research, and/or practice. Dr. Kyle will receive the award for his contributions to the study of multiple myeloma, monoclonal gammopathies, amyloidosis, and related plasma-cell disorders. Throughout his 50-year career as a physician-researcher, educator, and consultant, he has focused on defining these diseases, understanding their pathogenesis, presentation, and prognosis, and designing and evaluating therapeutic approaches. In addition, he has authored more than a thousand publications has trained more than 200 practicing hematologists.

These awards are named after notable figures in the Society's history and will be awarded during the 50th ASH Annual Meeting in December at the Moscone Center in San Francisco. Dr. Kyle will be presented with his award prior to the Plenary Scientific Session on Sunday, December 7, at 1:30 p.m. EST. Drs. Bloomfield and Anderson will be presented with their awards at the Presidential Symposium to be held on Tuesday, December 9, at 9:30 a.m. For the complete annual meeting schedule and additional information, please visit www.hematology.org/meetings/2008.
The American Society of Hematology (www.hematology.org) is the world's largest professional society concerned with the causes and treatment of blood disorders. Its mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems, by promoting research, clinical care, education, training, and advocacy in hematology.

American Society of Hematology

Related Multiple Myeloma Articles from Brightsurf:

Penn Study supports use of radiation before CAR therapy for multiple myeloma
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.

New multiple myeloma therapy shows promise in preclinical study
A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of The Journal of Nuclear Medicine.

A safer cell therapy harnesses patient T cells to fight multiple myeloma
A treatment for multiple myeloma that harnesses the body's cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease.

Colorado tool, My-DST, may pick best multiple myeloma treatment
Response of liquid biopsies to approved drugs can help show resistance, predict response.

Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.

New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options.

Single gene cluster loss may contribute to initiation/progression of multiple myeloma
The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

New CAR-T target yields promising results for multiple myeloma
In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy.

BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.

Read More: Multiple Myeloma News and Multiple Myeloma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.